Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01673854 · ClinicalTrials.gov registry record · Phase 2
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT01673854 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 70 participants.
The verdict
NCT01673854, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety profile of vemurafenib, 960 mg, administered for 6 weeks, followed by ipilimumab monotherapy in patients with BRAF V600 mutated advanced/metastatic melanoma.
Interventions
- DRUG Ipilimumab
- BIOLOGICAL Vemurafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2012-09-13 |
| Est. Completion | 2015-05-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01673854
The ClinicalTrials.gov registry entry for NCT01673854 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ipilimumab is the first listed.
NCT01673854 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01673854 about?
NCT01673854 is a clinical study titled "Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma". The purpose of this study is to assess the safety profile of vemurafenib, 960 mg, administered for 6 weeks, followed by ipilimumab monotherapy in patients with BRAF V600 mutated advanced/metastatic melanoma.
What is the current status of trial NCT01673854?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2012-09-13. Estimated completion is 2015-05-12.
What interventions are being tested in trial NCT01673854?
The interventions under investigation include: Ipilimumab (DRUG), Vemurafenib (BIOLOGICAL).
Who is sponsoring clinical trial NCT01673854?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.